JNJ
Johnson & Johnson
Price History
Why Is JNJ ▲ Up Today?
+1.23%
Johnson & Johnson Rises Following Q2 Earnings Report
Johnson & Johnson shares advanced today, significantly outperforming the broader healthcare sector. This positive movement appears to be a continued reaction to the company's Q2 2026 earnings report, which, despite some initial sentiment, is being viewed by investors as a buying opportunity.
Key Drivers
Generated by Highly Regarded's proprietary market analysis engine. Not financial advice.
Financial Highlights
Income Statement
Balance Sheet
Cash Flow
Highly Regarded Analysis
Executive Summary
Johnson & Johnson (JNJ) is a diversified global healthcare giant with a strong presence in Innovative Medicine and MedTech. The company recently reported robust Q2 2026 results, surpassing revenue and EPS estimates, and subsequently raised its full-year guidance, projecting to exceed $100 billion in annual revenue for the first time in its history. JNJ is recognized as a Dividend King, consistently increasing its dividend for over six decades, underpinned by strong cash flows and a solid balance sheet. While facing challenges such as patent expirations for key drugs and ongoing talc litigation, its extensive pipeline, strategic acquisitions, and focus on high-growth therapeutic areas position it for continued stability and growth.
Bull Case
The bull case for JNJ is supported by its diversified business model, strong performance in its Innovative Medicine and MedTech segments, and a robust product pipeline. Key growth drivers include blockbuster therapies like Darzalex and Tremfya, with several new indications and approvals anticipated. The company's raised full-year guidance and ongoing investments in R&D, including the Shockwave SkyRunner Carotid IVL system and the OTTAVA robotic system, are expected to fuel future growth. JNJ's defensive characteristics, consistent earnings, and status as a Dividend King make it an attractive long-term holding, especially amidst market volatility. Strategic acquisitions, such as Firefly Bio and Expanding Innovations, also contribute to its growth trajectory.
Bear Case
The bear case for JNJ centers on potential headwinds such as the patent cliff for high-revenue pharmaceutical products like STELARA, which has already seen a significant decline in sales due to biosimilar competition. Ongoing talc litigation represents a significant financial and reputational risk. The competitive landscape in key therapeutic areas like oncology and immunology could pressure future growth and profitability. Additionally, potential changes to healthcare reimbursement policies and ongoing supply chain volatility could impact manufacturing costs and overall performance. Morningstar recently downgraded JNJ to a 1-star (overvalued) rating, flagging it as trading at a 34% premium to its $190 fair value estimate, suggesting potential overvaluation.
Technical Outlook
JNJ stock closed at $252.45 on Friday, July 17th, reflecting a 1.14% increase from the previous trading session. Over the past 24 hours, the stock increased by 1.19%. While it experienced a -4.09% decline over the past week, it has risen 5.75% in the last month and demonstrated a significant 56.01% increase over the last year. The stock reached an all-time high of $269.43 on July 6, 2026. A recent post-earnings pullback is viewed by some analysts as a buying opportunity, indicating potential for a rebound. JNJ's beta coefficient of -0.41 suggests lower volatility compared to the broader market.
Fundamental Health
Johnson & Johnson exhibits robust fundamental health, with its Q2 2026 earnings beating analyst expectations for both EPS ($2.90 vs. $2.85 estimated) and revenue ($25.3 billion vs. $25.06 billion estimated). The company raised its full-year 2026 guidance, with expected reported sales of $100.8–$101.4 billion and adjusted diluted EPS of $11.60–$11.75. Innovative Medicine and MedTech segments are key growth drivers. JNJ maintains a healthy balance sheet with total shareholder equity of $81.2 billion and total debt of $55.0 billion, resulting in a manageable debt-to-equity ratio of 67.7%. Its interest coverage ratio is strong at 309.2. The company's dividend yield is 2.12% with a payout ratio of 62.11%, supported by 64 consecutive years of dividend increases, underscoring its financial stability and commitment to shareholder returns.
Key Catalysts
- Upcoming regulatory and clinical milestones in oncology, immunology, neuroscience, and MedTech.
- Expected approval and market penetration of the OTTAVA robotic system.
- Label expansion opportunities for key drugs such as Tremfya, Icotyde, Caplyta, and nipocalimab.
- Strategic acquisitions and partnerships.
- Continued strong performance and new launches in the Innovative Medicine and MedTech segments.
Sources
This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.
Go Deeper on JNJ
Key Stats
JNJ News
No recent news for JNJ.
